Progress and remaining challenges in comprehensive gastric cancer treatment

Zhi‐Feng Miao(Kaohsiung Medical University), Jiping Wang, Jiafu Ji(Peking University), Huimian Xu(First Hospital of China Medical University), Han Liang(Sun Yat-sen University), Hanyu Chen(First Hospital of China Medical University)

Holistic Integrative Oncology

April 28, 2022

10.1007/s44178-022-00002-z

Cited by 16

Related Papers

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

|Cancer Communications|2021|657

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial

|The Lancet Oncology|2021|436

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

|癌症：英文版|2023|412

Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study

|Clinical Cancer Research|2018|355

Variation in Gene Expression Patterns in Human Gastric Cancers

|Molecular Biology of the Cell|2003|319